Title: Chief Medical Officer
Company: NextCure, Inc.
Location: Bethesda, Maryland, United States
Han Myint, MD, chief medical officer at NextCure, Inc., has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in hematology and oncology.
With more than 30 years of experience to his credit, Dr. Myint has excelled as the chief medical officer at NextCure, Inc. since 2021, a position in which he leads the clinical development of novel therapies targeting tumor microenvironment, immune cells and cell of origin in various solid tumors and hematological malignancies. He began his career as a professor of hematology at King’s College London. Subsequently, he worked as a consultant hematologist and faculty member at the University of Southampton. He served as a member of IFIG from 1997 to 2001, immigrating to the United States soon thereafter. Notably, Dr. Myint has held an integral role in securing approval for several treatments of myeloid disorders by the U.S. Food and Drug Administration.
Dr. Myint continued his career at Rush University Medical Center as a visiting professor and director of the Hematology/Oncology Fellowship Program from 2001 to 2005. He transitioned to the role of founder and director of the Hematological Malignancies and Stem Cell Transplant Program at the University of Colorado Denver from 2005 to 2012. He found success as senior vice president of global medical affairs at Cell Therapeutics, Inc. from 2012 to 2013. He established himself as vice president of global medical affairs – MDS/AML at Celgene Corporation from 2013 to 2019. He garnered a stellar reputation as chief medical officer at NexImmune, Inc. from 2020 to 2021.
Before embarking on his professional path, Dr. Myint pursued an education at the Institute of Medicine, now the University of Medicine, in Yangon, Myanmar, where he earned a Bachelor of Medicine and Bachelor of Surgery. He pursued postgraduate training in internal medicine and hematology in the United Kingdom. In light of his impressive undertakings, he has accrued several accolades throughout his career. He was recognized among the Best Doctors in America between 2009 and 2012 and was frequently awarded bonuses by Celgene Corporation in acknowledgment of his outstanding contributions. He was inducted in Who’s Who in Montclair, named Pioneer of the Year, and contributed to efforts that were awarded Outstanding Service of the Year.
One of the notable highlights of Dr. Myint’s career was establishing the Hematological Malignancies and Stem Cell Transplant Program at the University of Colorado Denver. The program has been accredited by the Foundation for the Accreditation of Cellular Therapy and holds the prestigious designation as a Center of Excellence in stem cell transplantation. Today, the program is acknowledged as one of the leading global centers for stem cell transplantation. His contributions in the realm of myeloid diseases at Celgene Corporation were instrumental in securing FDA approval and successful market launches for four pharmaceutical products.
Dr. Myint attributes the solid foundation his parents crafted for him as instrumental in shaping his character and his success. As a testament to his distinguished impact on his field, he has been designated as an emeritus member of the American Society of Clinical Oncology and the American Society of Hematology. He is driven by a profound aspiration to leave the world better than when he entered it. In the immediate future, he is committed to continuing his work in advancing groundbreaking medical options.
For more information, please visit:
Contact Dr. Myint:
